Welcome to the Anderson Lab

Many patients with solid tumors are diagnosed at a late stage or develop chemotherapy-resistant disease, and then have few treatment options. Our major long-term goal is to advance therapies to address this critical gap in care. Our research program develops engineered T cell immunotherapies, integrating cellular and molecular techniques with in vivo mouse models and in vitro patient-based models of solid tumors to study the complex interactions between antitumor T cells and the tumor microenvironment. We have already established a robust portfolio of tools that target and enhance T cell persistence, function and metabolism, with real potential for clinical translation.